We could not find any results for:
Make sure your spelling is correct or try broadening your search.
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the...
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the US...
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the...
4SC AG (FWB:VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the US Food and Drug...
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results...
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data...
4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, has presented novel data on the mechanism of...
4SC AG (Frankfurt, Prime Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced the grant of an exclusive license by 4SC to Yakult Honsha for the development...
4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company, today announced that the first patient has been treated in the Phase I TOPAS study with 4SC-202...
4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.24 | -4.02684563758 | 5.96 | 6.18 | 5.64 | 1117 | 5.78599356 | DE |
4 | 1.49 | 35.2245862884 | 4.23 | 6.4 | 4.23 | 2556 | 5.68056726 | DE |
12 | 0.26 | 4.7619047619 | 5.46 | 6.4 | 3.82 | 2329 | 5.06515584 | DE |
26 | 0.9 | 18.6721991701 | 4.82 | 9.5 | 3.82 | 2439 | 5.65020901 | DE |
52 | -3.58 | -38.4946236559 | 9.3 | 10 | 3.82 | 2173 | 6.61452512 | DE |
156 | 2.755 | 92.9173693086 | 2.965 | 11.2 | 1.17 | 2541 | 5.19538898 | DE |
260 | 3.32 | 138.333333333 | 2.4 | 11.2 | 1.05 | 6241 | 2.60120165 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions